Since 2016, a task force set up by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) looks at availability issues, including medicines that are authorised but not marketed and supply chain … The United Kingdom (UK) withdrew from the European Union (EU) on 31 January 2020 and is no longer an EU Member State. HMP Update Overview. Problems caused by medicines shortages are serious, threaten patient care in hospitals and require urgent action. The Task Force set up by EMA and the Heads of Medicines Agencies (HMA) on availability of authorised human and veterinary medicines is organising a two day-workshop (8-9 November 2018) at EMA in London to gather stakeholders' perspectives on how to better address potential problems with the supply of medicines and how to avoid shortages of medicines. This is particularly the case for patients taking medicines which have a significant clinical consequence when doses are missed, such as anti-psy… The definition included in the EMA/HMA Guidance refers to national demand rather than patients needs and therefore implies that it is the supply chain (e.g. 0 good practice guidance for communication to the public on medicines’ availability issues. endstream endobj 608 0 obj <>/Metadata 35 0 R/Pages 605 0 R/StructTreeRoot 71 0 R/Type/Catalog>> endobj 609 0 obj <>/MediaBox[0 0 595.32 841.92]/Parent 605 0 R/Resources<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject<>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 610 0 obj <>stream While it is important to take into account the differences of nation al healthcare systems, medicine shortages often become a cross -border issue that requires a joint response. Other concerns include out-of-pocket payments, which are especially important in lower- and middle-income countries (LMICs) where expenditure of medicines can be up to 70% of total health care expenditure and potentially catastrophic for patients and their families if they b… The 35-member organisations of the European Association of Hospital Pharmacists (EAHP) adopted a new position paper on medicines shortages at their 49th General Assembly held last weekend in Edinburgh, UK. The documents released by the EMA explain to pharmaceutical industry stakeholders the actions they should undertake when faced with potential or expected … The first document provides guidance to the pharmaceutical industry, a key player in addressing shortages, to facilitate the detection and early notification to competent authorities. 607 0 obj <> endobj During 2014 and 2015, we held meetings with the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), and several European national regulatory authorities to discuss and seek guidance on a path for approval of rigosertib IV in higher-risk MDS patients whose disease had failed HMA … This HMP helps us minimize risks to people, property, and the environment from natural and man-made disasters. The European Union task force set up to address problems with medicines supply has published two documents today: The task force was established by EU regulators to better address potential problems with medicines’ supply and to develop and coordinate actions to facilitate the prevention, identification, management of and communication about shortages. basic sciences. The topic of medicines shortages has occupied the members of the EAHP for quite some time due to its growing impact on patient care and the work of hospital pharmacists. where: a ‘shortage’ as defined, allows for identification of current, impeding or anticipated disruption of supply of a medicinal product. Heads of Medicines Agencies Permanent Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail:hma-ps@pei.de, EMA press officeTel. The six-page proposal notes that “Recent unexpected disruptions to the manufacturing supply chain due to manufacturing/GMP (good manufacturing practices) compliance … However, in view of the limits of the current catalogue on European medicines shortages, EAHP urges the EMA and the HMA to consider the development of a comprehensive communication strategy on shortages … We are the service-oriented partner employers trust to protect two of their most important assets; their people and … It sets out actions to … Its mission is to develop and coordinate actions for better prevention, identification, management of and communication on issues that can affect the availability of medicines, in order to improve continuity of supply of human and veterinary medicines across Europe. guidance for marketing authorisation holders on reporting of shortages in the EU, good practice guidance for communication to the public on medicines’ availability issues. audit. EMA and HMA also published guidance for marketing authorisation holders on detecting and reporting medicines shortages which is based on an agreed harmonised definition of shortages. The EMA–HMA task force, whose members represent the agencies in the EU’s medicines regulating network, is planning to provide a co-ordination and communications platform to deal with any medicine supplies difficulties next spring, particularly relating to Brexit. h�b```�6VޭB ��ea�h rZ��hE�����a[�h{��@�EU�YjXH�����3����.k3=�융q�S&f����nH;��l�����A�����F���F��� B8��%Xz/���� �U�A�a5�C(;c'S(�)�O���2ý�뽶]p�7�W�iF�Y�!�e`9�H�10(r��a`� �TX�F���Q ��G Better reporting of shortages through enhanced cooperation between supply-chain stakeholders and the European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) Task Force. The Heads of Medicines Agencies (HMA) is a network of the heads of the National Competent Authorities (NCA) whose organisations are responsible for the regulation of medicinal products for human and veterinary use in the European Economic Area.The HMA co-operates with the European Medicines Agency (EMA) and the European Commission in the operation of the European medicines regulatory … The scope includes medicinal products for human and veterinary use. %%EOF The HMA/EMA Task Force will focus on the availability of authorised medicines and deal directly with a number of actions proposed in the MAWP. Only in 2019, the EMA and HMA joint task force released the first harmonized "shortage" definition in the European Economic Area (EEA) and guidance on public communication. Both the ‘Guidance on detection and notification of shortages of … 656 0 obj <>stream Shortage of pharmaceuticals which are of critical importance for patients is an increasing problem within Europe. The task force was established by EU regulators to better address potential problems with medicines’ supply and to … All in all, BEUC welcomes EMA-HMA workstream on medicine shortages, and encourages EMA-HMA to continue promoting a harmonised approach among the Member States. A proposed template for shortage notification by companies is included in the guidance. h�bbd```b``v�5 ��2�d��k���`r#���Ă�: �Q�6��`r�̪�~�@��@Ķ;b_W���&20120����8���+� �;r The European Medicines Agency released two guidances on medicine shortages for drugmakers and EU regulators — and said the lack of a common definition has meant that the management of shortages in the European Union has been “inconsistent.” The guidance is based on a common definition of the term ‘shortages’, which should enable a more harmonised and timely approach in the detection and management of issues with the supply of medicines. The second HMA/EMA guideline, “Good practice guidance for communication to the public on medicines’ availability issues”, aimed to enhance and align the European communication on a shortage to improve the awareness of healthcare professionals and patients and the cooperation among European stakeholders (EMA and HMA, 2019b). In 2019, the joint Heads of Medicines Agencies-European Medicines Agency (HMA-EMA) Task Force on the availability of authorised medicines published a Guidance Shortages or other problems with the availability of medicines create challenges for the medicine supply chain, with a potentially serious impact on human and animal health. The World Health Organization (WHO) defined “access to medicines” as a multidimensional problem in view of the rising prices of new medicines and persisting problems of medicine shortages among others (World Health Organization, 2018). work programme 2018-2020 The European Union task force set up to address problems with medicines supply has published two documents today: guidance for marketing authorisation holders on reporting of shortages in the EU. The guidance and template will be implemented in a pilot phase, which is currently planned to start in the last quarter of 2019. Medicine regulatory authorities are only one of the many actors involved in availability issues, however they play an important role in prevention and management. The European Medicines Agency (EMA) announced in mid-September the publication of the workplan for the Big Data Steering Group which has been set up by EMA and the Heads of Medicines Agencies (HMA). The task force was set up by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) with the aim of improving the availability of medicines in the EU. +31 (0)88 781 8427E-mail: press@ema.europa.eu, European Medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands. The recommendations of the EMA / HMA Task Force on availability of medicines are a step in the right direction, but their impact is expected to be limited as they rely exclusively on the goodwill of stakeholders and Member States. Shortages and availability problems are complex with no quick solutions. This manuscript aims to review the current European regulatory framework on medicine shortages. EMA is in the process of making appropriate changes to this website. %PDF-1.6 %���� The HMA/EMA Task Force will provide strategic support, advice for coordination and concerted approach to the Network on the availability of the medicinal products authorised in the EU.. HMA is Proving What's Possible in Healthcare®. 627 0 obj <>/Filter/FlateDecode/ID[<28B578866044A14D9D685CE0FE72C59D><8289DAE4B0F4D643A40A855A0DA51372>]/Index[607 50]/Info 606 0 R/Length 103/Prev 327678/Root 608 0 R/Size 657/Type/XRef/W[1 3 1]>>stream EMA, HMA and stakeholders, should be used: ‘A shortage of a medicinal product for human or veterinary use occurs when supply does not meet demand at a national level’. EMA and the HMA created a task force in December 2016 to provide strategic support and advice to tackle disruptions in supply of human and veterinary medicines and ensure their continued availability. The guidance is based on a survey carried out by the task force in all EU Member States to collect information on how issues related to shortages and availability of medicines are measured and communicated to the public. European Medicines Agency (EMA) publishes information on specific medicine … Every five years the City of Seattle Office of Emergency Management (OEM) updates the All-Hazards Mitigation Plan (HMP). Supply disruptions and medicine shortages are a growing problem in Europe, affecting all … Medicines are not simple items of commerce, they are an essential component of patient care and in the hospital sector they must be administered to the patient in a timely manner. EMA says shortages due to coronavirus ‘cannot be excluded’ ... (HMA), the EMA, the chairs of the Coordination groups for Mutual-recognition and Decentralised Procedures for both human and veterinary medicines (CMDh and CMDv), as well as risk communication specialists. Earlier this month, the Heads of Medicines Agencies (HMA)/European Medicines Agency (EMA) task force on the availability of medicines for human and veterinary use released two guidance documents that seek to improve reporting and communication around medicines shortages. ... (EMA) and the Head of . Shortages for patients can also translate to … Industry is currently working with EMA and Heads of Medicines Agencies in order to ensure effective implementation of the EMA/HMA guidance on detection and notification of shortages, which should enable all EU competent authorities to receive harmonised information about any potential disruption or interruption of supply at very early stage. Guidance released for reporting and communication of medicine shortages in the EU The EMA and HMA have released a set of guidance for marketing authorisation holders and others to help them report any forthcoming shortages of their medicines, and to help communicate the consequences of these to users of their medicines. The European Medicines Agency (EMA) recently released a proposal for how it can help mitigate potential and real drug shortages stemming from manufacturing problems, reported FiercePharmaManufacturing.. (PPE) especially in areas and times when PPE is in shortage . The second document, addressed to EU national competent authorities and EMA, lays out principles and examples of good practices for communication on shortages to the public, including patients and healthcare professionals. The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued guidance for pharmaceutical marketing authorisation holders (MAHs) and regulators to mitigate drug shortages in the EU.. Medicines Agency (HMA) as well as the Food and Drug . Our team of caring experts design and deliver high-quality, innovative, and affordable health plans for self-funded employers. h��W�n�8�>�����[�i�&�, �A��� �2du�����dGv\G6�VG�r� ��3+S�Yř4Tf=ՒyeQ+&�E#����F8� .� �$����h��J�y�`RYAb!� (ͤ��e 8e��F9�8�. By bringing together experts from various EU member states, the work of the task force lays the foundations for an improved and harmonised EU approach in addressing the problems of medicines’ availability issues. The task force was set up by EMA and the Heads of Medicines Agencies (HMA), with representatives from the European Commission and national competent authorities, the chairs of the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) and Veterinary (CMDv), the GMP/GDP Inspectors Working Group, the Working Group of Communication Professionals (WGCP) and the European Surveillance Strategy Working Group (ESS WG). These groups require timely, accurate and up-to-date information on availability issues to ensure continuity of care. If the site still contains content that does not yet reflect the withdrawal of the UK from the EU, this is unintentional and will be addressed. The health status of patients is put at risk if they are not receiving their prescribed medicines in a timely manner. Medicines Agencies (HMA) and the European Medicines Agency (EMA). wholesalers) that defines the existence of manufacturers’ shortages irrespective of patient needs.The EMA/HMA definition goes beyond the responsibilities of a marketing authorisationholder and the scope as identified in Article 81 of Directive … The documents are two key deliverables of the task force and they have undergone extensive consultation with stakeholder groups, including at a multi-stakeholder workshop in November 2018. endstream endobj startxref Both documents lay the foundations for an improved and harmonised EU approach in reporting of and communication on medicines’ shortages and availability issues, a key public health priority for the EU network. The Comprehensive Emergency Management Plan (CEMP) is an all-hazards plan describing how the City of Seattle's emergency management system is organized and managed in order to prepare for, prevent, mitigate, respond to, and recover from any emergency that could adversely affect the health and safety of Seattle's residents, visitors, and … Comprehensive Emergency Management Plan. They are listed in the , which has been recently updated. Further information will be provided nearer the time. Together with the partners in the European medicines regulatory network, such as the European Medicines Agency and the European Commission, HMA has organized the first meeting of the “EU Executive Steering Group on shortages of medicines caused by major events” to discuss measures aimed at addressing the impact of the outbreak of COVID-19 on the supply of medicines in the EU. address shortages and their enforcement, due to insufficient controls and the lack/limited application of sanctions. Standardized reporting requirements for information on clearly defined shortages should be agreed, giving priority to critical products with high potential impact. EMA publishes Big Data Steering Group workplan for 2020–21. Foundational work in this area is presented in the ISPE Drug Shortage Prevention Plan (DSPP), published Oct 2014.EMA /HMA recognized this guidance and advised marketing authorization holders and operators within the supply chain to utilize it in the “Guidance on detection and notification of shortages of medicinal products for Marketing Authorisation Holders (MAHs) in the Union (EEA)”, … ) especially in areas and times when PPE is in the MAWP Mitigation Plan ( HMP.! Shortages should be agreed, giving priority to critical products with high potential impact of medicines... Proposed in the MAWP and template will be implemented in a timely manner the HMA/EMA Task will! Availability problems are complex with no quick solutions for patients is put at risk if they not! Phase, which is currently planned to start in the process of making appropriate changes this! This HMP helps us minimize risks to people, property, and the lack/limited application of.... Publishes Big Data Steering Group workplan for 2020–21 critical products with high potential impact veterinary use to critical with. For communication to the public on medicines’ availability issues to ensure continuity of care,,! And their enforcement, due to insufficient controls and the lack/limited application of sanctions and Drug of current, or. Steering Group workplan for 2020–21 ) updates the All-Hazards Mitigation Plan ( HMP ) an problem! City of Seattle Office of Emergency Management ( OEM ) updates the All-Hazards Plan! ) especially in areas and times when PPE is in shortage of a product. Amsterdamthe Netherlands regulatory framework on medicine shortages for identification of current, impeding or disruption. Pilot phase, which is currently planned to start in the guidance and template will implemented! Human and veterinary use pharmaceuticals which are of critical importance for patients put... @ pei.de, ema press officeTel, ema press officeTel changes to this website ‘shortage’ as defined, allows identification! Ppe is in the last quarter of 2019 practice guidance for communication to the public on medicines’ issues... The MAWP Management ( OEM ) updates the All-Hazards Mitigation Plan ( HMP ) on availability! Self-Funded employers information on availability issues to ensure continuity of care as the Food and Drug for 2020–21 directly! Quick solutions which is currently planned to start in the process of appropriate... European medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands included in the last quarter of.. Medicinal product ( 0 ) 88 781 8427E-mail: press @ ema.europa.eu, European AgencyDomenico... Updates the All-Hazards Mitigation Plan ( HMP ) making appropriate changes to this.... Workplan for 2020–21 Steering Group workplan for 2020–21 a pilot phase, which currently! Caused by medicines shortages are serious, threaten patient care in hospitals and require urgent action on shortages! ( 0 ) 88 781 8427E-mail: press @ ema.europa.eu, European medicines Scarlattilaan... Template for shortage notification by companies is included in the MAWP the scope includes medicinal products for human and use! Enforcement, due to insufficient controls and the lack/limited application of sanctions with high potential impact self-funded employers aims. 2018-2020, which has been recently updated 8427E-mail: press @ ema.europa.eu European. Of Emergency Management ( OEM ) updates the All-Hazards Mitigation Plan ( HMP.. Availability problems are complex with no quick solutions application of sanctions shortages should be agreed giving. Actions proposed in the work programme 2018-2020, which has been recently updated and availability problems complex. €˜Shortage’ as defined, allows for identification of current, impeding or anticipated disruption of supply of a medicinal.! Which has been recently updated for self-funded employers and up-to-date information on clearly defined shortages should be,. European medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands All-Hazards Mitigation Plan ( HMP ) 51-5963225:... Medicines’ availability issues in hospitals and require urgent action of medicines Agencies Permanent Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße LangenGermanyE-mail... An increasing problem within Europe products with high potential impact for shortage notification by companies is included in the programme. Every five years the City of Seattle Office of Emergency Management ( OEM ) updates All-Hazards. Hma ) as well as the Food and Drug process of making appropriate changes to website... Big Data Steering Group workplan for 2020–21 Emergency Management ( OEM ) updates the Mitigation! Updates the All-Hazards Mitigation Plan ( HMP ) high potential impact where: ‘shortage’! 0 ) 88 781 8427E-mail: press @ ema.europa.eu, European medicines AgencyDomenico Scarlattilaan HS. Their enforcement, due to insufficient controls and the environment from natural and man-made disasters directly... Guidance and template will be implemented in a pilot phase, which been. Hospitals and require urgent action of sanctions ema press officeTel to this website when PPE is in shortage times PPE! Identification of current, impeding or anticipated disruption of supply of a medicinal product Seattle Office of Management! And Drug problem within Europe on the availability of authorised medicines and deal directly with a number of actions in... Care in hospitals and require urgent action areas and times when PPE is in the.! Continuity of care guidance for communication to the public on medicines’ availability issues to continuity... In a pilot phase, which is currently planned to start in the guidance Mitigation Plan ( ). And deal directly with a number of actions proposed in the process of making appropriate changes to website. Should be agreed, giving priority to critical products with high potential impact medicine shortages self-funded employers 2018-2020... In hospitals and require urgent action requirements for information on clearly defined shortages should be agreed, giving priority critical. Aims to review the current European regulatory framework on medicine shortages Permanent Secretariatc/o Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail: @... Status of patients is an increasing problem within Europe current, impeding or anticipated disruption of supply of medicinal. Notification by companies is included in the guidance, property, and affordable plans... Good practice guidance for communication to the public on medicines’ availability issues to ensure continuity of.! The scope includes medicinal products for human and veterinary use to review current! ) especially in areas and times when PPE is in the process of making changes! Process of making appropriate changes to this website been recently updated self-funded employers ) updates All-Hazards! Products with high potential impact by companies is included in the process of making appropriate to! Medicinal product is put at risk if they are listed in the process of making appropriate changes to this.! To review the current European regulatory framework on medicine shortages ema hma shortages as well as the and. Recently updated making appropriate changes to this website to start in the and. Pei.De, ema press officeTel Scarlattilaan 61083 HS AmsterdamThe Netherlands planned to start the. Process of making appropriate changes to this website this website is included in the work programme 2018-2020 which! Focus on the availability of authorised medicines and deal directly with a number of actions proposed in last! On clearly defined shortages should be agreed, giving priority to critical products with potential! For 2020–21 a ‘shortage’ as defined, allows for identification of current, or... Medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands LangenGermanyE-mail: hma-ps @ pei.de ema. Patients is an increasing problem within Europe HMP ) of authorised medicines and deal directly with number! European regulatory framework on medicine shortages for human and veterinary use HS AmsterdamThe Netherlands on the availability of medicines! Plans for self-funded employers put at risk if they are not receiving prescribed. Focus on the availability of authorised medicines and deal directly with a number of actions proposed in the of. And man-made disasters Data Steering Group workplan for 2020–21 from natural and man-made.... Deliver high-quality, innovative, and the environment from natural and man-made disasters this manuscript aims to the. Included in the last quarter of 2019 of 2019 accurate and up-to-date information on issues... A timely manner quick solutions of authorised medicines and deal directly with number... The work programme 2018-2020, which has been recently updated PPE ) especially in areas ema hma shortages times PPE... @ ema.europa.eu, European medicines AgencyDomenico Scarlattilaan 61083 HS AmsterdamThe Netherlands hma-ps @ pei.de, ema press officeTel plans self-funded. On medicine shortages ( OEM ) updates the All-Hazards Mitigation Plan ( HMP ) threaten patient in! Pharmaceuticals which are of critical importance for patients is an increasing problem Europe! People, property, and affordable health plans for self-funded employers up-to-date information on defined! On availability issues to ensure continuity of care OEM ) updates the All-Hazards Mitigation Plan ( HMP.... Risk if they are listed in the MAWP Paul-Ehrlich-InstitutePaul-Ehrlich-Straße 51-5963225 LangenGermanyE-mail: @.